PASSAGE BIO INC. - COMMON STOCK

U.S. Food and Drug Administration Grants Fast Track Designation to Three Passage Bio Gene Therapy Candidates Targeting Rare CNS Disorders

08 Mar 2021 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Business Highlights

03 Mar 2021 07:00:01 By Nasdaq GlobeNewswire

Passage Bio to Participate in Upcoming March Investor Conferences

02 Mar 2021 16:01:00 By Nasdaq GlobeNewswire

Passage Bio to Report Fourth Quarter and Full-Year 2020 Financial Results on March 3, 2021

24 Feb 2021 07:00:01 By Nasdaq GlobeNewswire

Passage Bio Appoints Maxine Gowen, Ph.D. to Board of Directors

19 Feb 2021 07:00:00 By Nasdaq GlobeNewswire

FDA Clears IND Application for Passage Bio’s Gene Therapy Candidate PBKR03 for Treatment of Patients with Early Infantile Krabbe Disease, A Rare Pediatric Disorder with No Approved Disease-Modifying Treatment Options

08 Feb 2021 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Receives FDA Clearance of IND Application for PBFT02 Gene Therapy Candidate for Treatment of Patients with Frontotemporal Dementia with Granulin Mutations

28 Jan 2021 07:00:01 By Nasdaq GlobeNewswire

Passage Bio Announces Pricing of Public Offering

21 Jan 2021 19:48:12 By Nasdaq GlobeNewswire

Passage Bio Announces Launch of Proposed Public Offering

19 Jan 2021 16:05:50 By Nasdaq GlobeNewswire

Passage Bio to Host First of a Series of 2021 Virtual R&D Events on January 25

19 Jan 2021 07:00:00 By Nasdaq GlobeNewswire

Passage Bio Announces Plan to Deliver on Multiple Meaningful Catalysts in 2021

11 Jan 2021 07:00:01 By Nasdaq GlobeNewswire

Passage Bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

04 Jan 2021 16:01:00 By Nasdaq GlobeNewswire

Passage Bio Receives FDA Clearance of IND Application for Lead Gene Therapy Candidate PBGM01 for Treatment of Infantile GM1 Gangliosidosis

04 Jan 2021 07:00:00 By Nasdaq GlobeNewswire